Cellebrite DI's (CLBT) Sell (D+) Rating Reaffirmed at Weiss Ratings

Key Points

• Weiss Ratings has reaffirmed its "sell (d+)" rating for Cellebrite DI (NASDAQ: CLBT), indicating continued caution about the stock's performance.
• Despite the sell rating from Weiss, JP Morgan Chase recently increased its price target for the stock to $23.00, while Needham & Company lowered its target to $18.00, reflecting mixed sentiments among analysts.
• Cellebrite DI reported a year-over-year revenue increase of 18.4%, with the most recent earnings per share at $0.12, surpassing analyst expectations by a slight margin.

Cellebrite DI (NASDAQ:CLBT - Get Free Report)'s stock had its "sell (d+)" rating restated by investment analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Several other analysts also recently commented on CLBT. JPMorgan Chase & Co. upped their price objective on Cellebrite DI from $20.00 to $23.00 and gave the company an "overweight" rating in a research note on Wednesday, September 24th. Needham & Company LLC lowered their target price on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. Wall Street Zen upgraded Cellebrite DI from a "hold" rating to a "buy" rating in a report on Friday, September 26th. Finally, Lake Street Capital cut their target price on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research report on Friday, August 15th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Cellebrite DI currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.75.

Cellebrite DI Stock Performance

Shares of NASDAQ:CLBT traded up $0.50 during trading on Wednesday, reaching $18.99. The stock had a trading volume of 882,983 shares, compared to its average volume of 1,503,932. Cellebrite DI has a 1-year low of $13.10 and a 1-year high of $26.30. The stock has a market cap of $4.55 billion, a PE ratio of 54.38, a PEG ratio of 3.36 and a beta of 1.29. The business has a fifty day moving average price of $16.50 and a 200-day moving average price of $16.98.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The company had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. During the same quarter in the previous year, the business earned $0.10 earnings per share. The company's revenue for the quarter was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts expect that Cellebrite DI will post 0.3 earnings per share for the current year.

Hedge Funds Weigh In On Cellebrite DI

A number of hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its holdings in shares of Cellebrite DI by 46.2% during the 1st quarter. SG Americas Securities LLC now owns 306,287 shares of the company's stock valued at $5,951,000 after acquiring an additional 96,758 shares during the last quarter. Handelsbanken Fonder AB lifted its position in Cellebrite DI by 749.9% during the 1st quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock worth $29,508,000 after buying an additional 1,340,000 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in Cellebrite DI during the 1st quarter worth about $269,000. Strategic Advisors LLC raised its holdings in Cellebrite DI by 137.9% during the 1st quarter. Strategic Advisors LLC now owns 69,198 shares of the company's stock worth $1,345,000 after purchasing an additional 40,116 shares during the last quarter. Finally, Manning & Napier Advisors LLC bought a new stake in shares of Cellebrite DI in the 1st quarter valued at about $1,979,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.